

# Keisuke Hino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3974372/publications.pdf>

Version: 2024-02-01

98  
papers

11,000  
citations

126907

33  
h-index

51608

86  
g-index

100  
all docs

100  
docs citations

100  
times ranked

20388  
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron and liver cancer: an inseparable connection. FEBS Journal, 2022, 289, 7810-7829.	4.7	27
2	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. Cancers, 2022, 14, 454.	3.7	9
3	Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.. Journal of Clinical Oncology, 2022, 40, 417-417.	1.6	14
4	Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 739-762.	4.5	29
5	Correlation of hepatitis C virus-mediated endoplasmic reticulum stress with autophagic flux impairment and hepatocarcinogenesis. Medical Molecular Morphology, 2021, 54, 108-121.	1.0	7
6	Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report. BMC Gastroenterology, 2021, 21, 111.	2.0	5
7	Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines. Scientific Reports, 2021, 11, 3703.	3.3	5
8	Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. Hepatology Research, 2021, 51, 957-967.	3.4	39
9	TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2021, 39, 270-270.	1.6	25
10	Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut, 2020, 69, 1492-1501.	12.1	411
11	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Science, 2020, 111, 3759-3769.	3.9	29
12	2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity. Journal of Hepatology, 2020, 73, S641.	3.7	0
13	Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S686-S687.	3.7	0
14	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. PLoS ONE, 2020, 15, e0219412.	2.5	17
15	Iron loss triggers mitophagy through induction of mitochondrial ferritin. EMBO Reports, 2020, 21, e50202.	4.5	64
16	Title is missing!. , 2020, 15, e0219412.		0
17	Title is missing!. , 2020, 15, e0219412.		0
18	Title is missing!. , 2020, 15, e0219412.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0219412.		0
20	Role of Oxidative Stress in Alcoholic/Non-Alcoholic Liver Diseases. , 2019, , 113-125.		0
21	Iron as Soul of Life on Earth Revisited: From Chemical Reaction, Ferroptosis to Therapeutics. Free Radical Biology and Medicine, 2019, 133, 1-2.	2.9	6
22	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer, 2019, 8, 505-519.	7.7	20
23	Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection. Free Radical Biology and Medicine, 2019, 133, 193-199.	2.9	34
24	Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 115-134.	4.5	70
25	Liver Cirrhosis with Inherited Liver Disease: Hemochromatosis. , 2019, , 47-57.		1
26	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 424-432.	8.1	216
27	<sc><i>Wisteria floribunda</i></sc> agglutininâ€positive Macâ€2 binding protein predicts the development of hepatocellular carcinoma in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2018, 48, 521-528.	3.4	19
28	Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 58-68.	4.3	42
29	Key HLAâ€DRB1â€DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology, 2018, 68, 848-858.	7.3	53
30	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. Journal of Gastroenterology, 2018, 53, 247-257.	5.1	15
31	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. Scientific Reports, 2018, 8, 7958.	3.3	38
32	Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.. Journal of Clinical Oncology, 2018, 36, 4017-4017.	1.6	8
33	Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.. Journal of Clinical Oncology, 2018, 36, 206-206.	1.6	29
34	Assessment of clinical and magnetic resonance imaging features of de novo hypervascular hepatocellular carcinoma using gadoxetic acidâ€enhanced magnetic resonance imaging. Hepatology Research, 2017, 47, E152-E160.	3.4	4
35	Acyl/free carnitine ratio is a risk factor for hepatic steatosis after pancreatoduodenectomy and total pancreatectomy. Pancreatology, 2017, 17, 135-138.	1.1	5
36	Assessment of hepatic fibrosis with superb microvascular imaging in hepatitis C virusâ€associated chronic liver diseases. Hepatology Research, 2017, 47, 593-597.	3.4	16

#	ARTICLE	IF	CITATIONS
37	L-Carnitine Supplementation Improved Hepatic Steatosis After Pancreatectomy. <i>Pancreas</i> , 2016, 45, e7-e9.	1.1	1
38	Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. <i>Hepatology Research</i> , 2016, 46, 951-963.	3.4	463
39	Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. <i>Scientific Reports</i> , 2016, 6, 24767.	3.3	39
40	Assessment criteria for sarcopenia in liver disease (first edition): Report from the working group for creation of sarcopenia assessment criteria in the Japan Society of Hepatology. <i>Acta Hepatologica Japonica</i> , 2016, 57, 623-633.	0.1	1
41	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
42	Emergent laparoscopic cholecystectomy for acute acalculous cholecystitis revisited. <i>Surgery Today</i> , 2016, 46, 309-312.	1.5	9
43	Metal Metabolism and Liver. , 2016, , 123-146.		5
44	A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model. <i>PLoS ONE</i> , 2016, 11, e0154676.	2.5	14
45	Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0164418.	2.5	9
46	Assessment criteria for sarcopenia in liver disease (first edition): Report from the working group for creation of sarcopenia assessment criteria in the Japan Society of Hepatology. <i>Acta Hepatologica Japonica</i> , 2016, 57, 353-368.	0.1	6
47	Fibroblast activation protein-1-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. <i>BMC Gastroenterology</i> , 2015, 15, 109.	2.0	75
48	Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2015, 50, 776-784.	5.1	141
49	Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. <i>Human Genetics</i> , 2015, 134, 279-289.	3.8	13
50	Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice. <i>Liver International</i> , 2015, 35, 1303-1314.	3.9	23
51	New Susceptibility and Resistance HLA-DP Alleles to HBV-Related Diseases Identified by a Trans-Ethnic Association Study in Asia. <i>PLoS ONE</i> , 2014, 9, e86449.	2.5	40
52	Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 762-768.	2.0	191
53	Hepatic oxidative stress in ovariectomized transgenic mice expressing the hepatitis C virus polyprotein is augmented through suppression of adenosine monophosphate-activated protein kinase/proliferator-activated receptor gamma co-activator 1 alpha signaling. <i>Hepatology Research</i> , 2014, 44, F229-39.	3.4	3
54	Mitochondrial reactive oxygen species as a mystery voice in hepatitis C. <i>Hepatology Research</i> , 2014, 44, 123-132.	3.4	23

#	ARTICLE	IF	CITATIONS
55	Hepatitis C Virus Core Protein Suppresses Mitophagy by Interacting with Parkin in the Context of Mitochondrial Depolarization. <i>American Journal of Pathology</i> , 2014, 184, 3026-3039.	3.8	56
56	Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer. <i>Anticancer Research</i> , 2014, 34, 3125-9.	1.1	13
57	Prevalence and outcomes of acute hepatitis B in Okayama, Japan, 2006-2010. <i>Acta Medica Okayama</i> , 2014, 68, 243-7.	0.2	2
58	Iron metabolic disorder in chronic hepatitis C: Mechanisms and relevance to hepatocarcinogenesis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 93-98.	2.8	33
59	First jejunal vein oriented mesenteric excision for pancreatoduodenectomy. <i>Journal of Gastroenterology</i> , 2013, 48, 989-995.	5.1	30
60	Clinical usefulness of non- $\epsilon$ protein respiratory quotient measurement in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2013, 43, 1284-1294.	3.4	5
61	Risk Factors for Survival and the Development of Hepatocellular Carcinoma in Patients with Primary Biliary Cirrhosis. <i>Internal Medicine</i> , 2013, 52, 1553-1559.	0.7	30
62	Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study. <i>Hepatic Medicine: Evidence and Research</i> , 2013, 5, 11.	2.5	20
63	A follow-up survey of hepatitis virus carriers after notification of their infection in Okayama prefecture. <i>Acta Hepatologica Japonica</i> , 2013, 54, 84-86.	0.1	1
64	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , 2012, 13, 47.	2.1	40
65	Temperature-Related Effects of Adenosine Triphosphate-Activated Microglia on Pro-Inflammatory Factors. <i>Neurocritical Care</i> , 2012, 17, 293-300.	2.4	20
66	Iron metabolic disorder in chronic hepatitis C: insights from recent evidence. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 251-256.	0.8	1
67	Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean. <i>PLoS ONE</i> , 2012, 7, e39175.	2.5	137
68	The rs8099917 Polymorphism, When Determined by a Suitable Genotyping Method, Is a Better Predictor for Response to Pegylated Alpha Interferon/Ribavirin Therapy in Japanese Patients than Other Single Nucleotide Polymorphisms Associated with Interleukin-28B. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1853-1860.	3.9	68
69	Recommendation of lamivudine to entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. <i>Hepatology Research</i> , 2011, 41, 505-511.	3.4	4
70	Type I interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma. <i>Hepatic Medicine: Evidence and Research</i> , 2011, 3, 45.	2.5	0
71	Focal Nodular Hyperplasia-Like Nodule with Reduced Expression of Organic Anion Transporter 1B3 in Alcoholic Liver Cirrhosis. <i>Internal Medicine</i> , 2011, 50, 1193-1199.	0.7	11
72	A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice. <i>Liver International</i> , 2011, 31, 552-560.	3.9	31

#	ARTICLE	IF	CITATIONS
73	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. <i>Human Molecular Genetics</i> , 2011, 20, 3507-3516.	2.9	85
74	3. Iron Metabolism Disorders and Iron Reduction Therapy in Patients with Chronic Liver Diseases.. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 1248-1254.	0.0	1
75	Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. <i>Liver International</i> , 2010, 30, 683-692.	3.9	28
76	Molecular typing of <i>Bartonella henselae</i> DNA extracted from human clinical specimens and cat isolates in Japan. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 44-48.	2.7	9
77	Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). <i>Hepatology Research</i> , 2010, 40, 347-368.	3.4	40
78	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C. <i>Acta Hepatologica Japonica</i> , 2009, 50, 665-677.	0.1	0
79	Distribution of Hepatitis B Virus Genotypes among Patients with Chronic Infection in Japan Shifting toward an Increase of Genotype A. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1476-1483.	3.9	114
80	Genome-wide association of IL28B with response to pegylated interferon- $\alpha$ and ribavirin therapy for chronic hepatitis C. <i>Nature Genetics</i> , 2009, 41, 1105-1109.	21.4	2,124
81	Direct Cytopathic Effects of Particular Hepatitis B Virus Genotypes in Severe Combined Immunodeficiency Transgenic With Urokinase-Type Plasminogen Activator Mouse With Human Hepatocytes. <i>Gastroenterology</i> , 2009, 136, 652-662.e3.	1.3	56
82	Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication. <i>Liver International</i> , 2008, 28, 1158-1166.	3.9	20
83	Hepatitis C Virus-Induced Reactive Oxygen Species Raise Hepatic Iron Level in Mice by Reducing Hecpidin Transcription. <i>Gastroenterology</i> , 2008, 134, 226-238.	1.3	242
84	Clinical predictor for development of hepatocellular carcinoma in patients with primary biliary cirrhosis. <i>Acta Hepatologica Japonica</i> , 2008, 49, 449-451.	0.1	3
85	Stronger Neo-Minophagen C?, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein. <i>Liver International</i> , 2007, 27, 845-853.	3.9	28
86	Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. <i>Journal of Gastroenterology</i> , 2007, 42, 407-409.	5.1	6
87	Hepatic Iron Overload Induces Hepatocellular Carcinoma in Transgenic Mice Expressing the Hepatitis C Virus Polyprotein. <i>Gastroenterology</i> , 2006, 130, 2087-2098.	1.3	155
88	417- $\alpha$ -Tocopherol and ascorbic acid attenuates the ribavirin-induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1269-1275.	2.8	17
89	Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. <i>Hepatology Research</i> , 2006, 36, 107-114.	3.4	60
90	Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial reactive oxygen species. <i>Journal of Gastroenterology</i> , 2006, 41, 257-268.	5.1	38

#	ARTICLE	IF	CITATIONS
91	Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon $\alpha$ -2b and ribavirin. <i>Nutrition</i> , 2006, 22, 114-122.	2.4	20
92	Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. <i>Hepatology</i> , 2006, 44, 326-334.	7.3	222
93	Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. <i>Journal of Medical Virology</i> , 2005, 77, 39-46.	5.0	60
94	In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. <i>Journal of Gastroenterology</i> , 2005, 40, 617-624.	5.1	36
95	Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 1305-1311.	2.8	17
96	Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. <i>Journal of Gastroenterology</i> , 2004, 39, 1069-1077.	5.1	64
97	Hepatitis B virus genotype G is an extremely rare genotype in Japan. <i>Hepatology Research</i> , 2004, 30, 199-203.	3.4	11
98	Analysis of lymphoid follicles in liver of patients with chronic hepatitis C. <i>Liver</i> , 1992, 12, 387-391.	0.1	28